Transcatheter Aortic Valve Replacement (TAVR) Adoption (2002-2020)
French cardiologist Alain Cribier performed the first transcatheter aortic valve replacement in 2002 on a patient too sick for open-heart surgery. Initially restricted to patients at prohibitive surgical risk, the procedure gradually expanded as trials demonstrated safety and efficacy. By 2020, TAVR was approved for patients at all risk levels.
High-risk patients who would have died received a treatment option. Early TAVR required large catheters causing vascular complications.
TAVR now accounts for a majority of aortic valve replacements in the US. Catheter sizes have shrunk from 24-25 French to 14-16 French. Patients typically go home the next day.
VECTOR follows the same trajectory TAVR established: starting with patients who have no other options, then potentially expanding to broader populations as the technique matures and long-term data accumulates.
